论文部分内容阅读
目的探讨检测肝病患者血清前白蛋白的临床应用价值。方法对149例肝病患者同时测定血清前白蛋白(PAB)、总蛋白、白蛋白,并对115例肝病患者治疗前后的血清前白蛋白进行动态观察。结果各肝病组血清前白蛋白水平显著低于健康对照组(P<0.01),急性肝炎组79.5%的病例PAB水平下降,而仅9.7%的病例白蛋白下降,两者比较差异有统计学意义(P<0.01)。各肝病组治疗后1个月与治疗前相比,血清PAB水平明显升高(P<0.01或P<0.05)。结论血清PAB较常规肝功能指标中的总蛋白、白蛋白能更灵敏、快速地反映肝病患者肝脏功能的损害程度,并有助于肝病的疗效观察。
Objective To investigate the clinical value of detecting prealbumin in patients with liver disease. Methods Serum prealbumin (PAB), total protein and albumin were measured simultaneously in 149 patients with liver disease. Serum prealbumin was detected in 115 patients with liver disease before and after treatment. Results Serum prealbumin levels were significantly lower in each liver disease group than in the healthy control group (P <0.01). In acute hepatitis group, PAB level decreased in 79.5% of cases and decreased in 9.7% of cases, with significant difference between the two groups (P <0.01). Compared with before treatment, serum PAB level in each liver disease group was significantly increased at 1 month (P <0.01 or P <0.05). Conclusions Serum PAB is more sensitive and faster than the total protein and albumin in liver function indexes, and it can reflect the damage of liver function in patients with liver disease and contribute to the curative effect of liver disease.